An integrative method for scoring candidate genes from association studies: application to warfarin dosing by Tatonetti, Nicholas P et al.
PROCEEDINGS Open Access
An integrative method for scoring candidate
genes from association studies: application to
warfarin dosing
Nicholas P Tatonetti
1,4†, Joel T Dudley
1,2†, Hersh Sagreiya
3, Atul J Butte
2, Russ B Altman
4*
From 2010 AMIA Summit on Translational Bioinformatics
San Francisco, CA, USA. 10-12 March 2010
Abstract
Background: A key challenge in pharmacogenomics is the identification of genes whose variants contribute to
drug response phenotypes, which can include severe adverse effects. Pharmacogenomics GWAS attempt to
elucidate genotypes predictive of drug response. However, the size of these studies has severely limited their
power and potential application. We propose a novel knowledge integration and SNP aggregation approach for
identifying genes impacting drug response. Our SNP aggregation method characterizes the degree to which
uncommon alleles of a gene are associated with drug response. We first use pre-existing knowledge sources to
rank pharmacogenes by their likelihood to affect drug response. We then define a summary score for each gene
based on allele frequencies and train linear and logistic regression classifiers to predict drug response phenotypes.
Results: We applied our method to a published warfarin GWAS data set comprising 181 individuals. We find that
our method can increase the power of the GWAS to identify both VKORC1 and CYP2C9 as warfarin
pharmacogenes, where the original analysis had only identified VKORC1. Additionally, we find that our method can
be used to discriminate between low-dose (AUROC=0.886) and high-dose (AUROC=0.764) responders.
Conclusions: Our method offers a new route for candidate pharmacogene discovery from pharmacogenomics
GWAS, and serves as a foundation for future work in methods for predictive pharmacogenomics.
Background
Genome-wide association studies (GWAS), which gener-
ally assay common variation and rely on relatively large
effects, are now being widely applied to perform gen-
ome-wide scans for variants associated with pharmaco-
logical phenotypes [1,2]. In the case of complex diseases,
GWAS have yielded associated variants with modest
overall effects. However, in the case of pharmacological
phenotypes, initial results from pharmacogenomic
GWAS appear to indicate a greater ability to discover
variants with substantial effect size [1,3]. Nevertheless,
pharmacogenomic GWAS suffer many of the limitations
of disease GWAS in that follow up studies are often
required to elucidate the causative genes and variants
latent in the GWAS results [4-6]. Additionally, pharma-
cogenomic GWAS are also limited in power by small
cohort sizes [7]. Amongst the drugs whose pharmacolo-
gical variance has been evaluated using the GWAS
approach, warfarin (Coumadin) has emerged as a promi-
nent pharmacogenomics case study with great transla-
tional potential.
Given the its broad use, narrow therapeutic range, and
severity of side effects, a comprehensive pharmacogenomic
characterization of warfarin dose-response offers the
potential for substantial clinical impact [8,9]. Retrospective
studies revealed the role of VKORC1, CYP2C9, and
CYP4F2 in mediating abnormal variations in warfarin dose
response [10-12], explaining approximately 30%, 10% and
5% of the variance in drug response respectively [13]. The
relationship between variants in these genes and atypical
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by GWAS analysis [14,15]. Recently, a method to estimate
stable warfarin dose was developed by integrating informa-
tion on patient VKORC1 and CYP2C9 genotypes with
clinical factors [16]. Although this method incorporated
genotype information for only two warfarin pharmaco-
genes, the genotype-based method was able to explain
~49% of the variance in stable dose, substantially outper-
forming the pure-clinical and fixed-dose approaches. The
elucidation of additional large-effect pharmacogenes for
warfarin and other genomic features might serve to dra-
matically increase the ability to predict warfarin dose
response from genotype.
Therefore, in this study, we propose a novel method
for increasing the power of pharmacogenomic GWAS
and detecting pharmacogenes predictive of drug
response. Our method characterizes the degree to which
uncommon alleles of a gene correlate with drug
response. If uncommon alleles are associated with atypi-
cal drug response phenotypes, then the gene is consid-
ered a predictive pharmacogene and a putative marker
for drug response.
Results
Using knowledge to limit the hypothesis testing space
We identified 228 genes which were likely to be phar-
macogenes for warfarin and which also contained SNPs
measured in the Cooper warfarin response GWAS data
set (See Methods). There were 3,856 SNPs contained
within these 228 genes. We tested each of the 3,856
SNPs with a univariate linear regression model for its
ability to predict warfarin dosage, the exact analysis per-
f o r m e db yC o o p e r ,e ta l . ,h o w e v e r ,w i t ht h ea d v a n t a g e
of testing fewer hypotheses. As expected, the results of
this analysis closely resemble the results of the Cooper
analysis except that a much less strict significance
threshold is necessary to correct for multiple hypothesis
testing (1.3e-5 as opposed to 1.0e-7). However, even
with this lower threshold only one SNP, rs10871454
(VKORC1), was significant after correction (Table 1).
Derivation and evaluation of a candidate gene-score
based on allele frequencies
W assigned each SNP to a gene if the SNP was within 5
kbp of the boundary of the gene. Some SNPs mapped to
more than one gene. We then aggregated the SNPs into
genes using this mapping and calculate each gene’s
pHap gene-scores (See Methods). Each gene-score was
then tested with a univariate linear regression model for
its ability to predict warfarin dosage, again, the same
analysis performed by Cooper, except that we now are
testing only 228 hypotheses and each gene-score is a
summary of a set of SNPs frequencies. In this analysis
both VKORC1 and CYP2C9 are significant for
predicting stable warfarin dosage (Table 2). VKORC1
and CYP2C9 pass the corrected significance threshold
of 1e-3 with p-values of 9.1e-7 and 9.6e-5 respectively.
Extreme dose response warfarin response models
The gene-score was calculated for each of the 228 genes
in the WSP for each patient in two classes: low dose
patients and the compliment. The distributions of gene-
scores of the two classes were tested for the null
hypothesis, namely that the means of the distributions
were equal. Two genes significantly distinguish the two
classes after corrected for multiple hypothesis testing,
VKORC1 and UBE3A with p-values of 1.2e-4 and 5.4e-5
respectively. 18 other genes had p-values that were less
Table 1 Knowledge filtered significant SNPs
SNP Gene Name P-Value
rs10871454 VKORC1 Vitamin K1 2,3-epoxide
reductase subunit 1
9.31E-10
rs4086116 CYP2C9 cytochrome P450, family 2,
subfamily C
7.54E-05
rs4917639 CYP2C9 cytochrome P450, family 2,
subfamily C
9.47E-05
rs9332169 CYP2C9 cytochrome P450, family 2,
subfamily C
2.33E-04
rs9332214 CYP2C9 cytochrome P450, family 2,
subfamily C
2.33E-04
rs10509680 CYP2C9 cytochrome P450, family 2,
subfamily C
2.33E-04
rs12445568 HSD3B7 3-beta-HSD VII 3.84E-04
rs12357515 EXOC6 Exocyst complex component
Sec15A
3.86E-04
rs11187215 EXOC6 Exocyst complex component
Sec15A
3.87E-04
rs7294 VKORC1 Vitamin K1 2,3-epoxide
reductase subunit 1
4.15E-04
Top 10 of 3,856 SNPs fitting a univariate linear regression model of warfarin
dose for 181 patients. Bold SNPs are significant after multiple hypothesis
testing. Only rs10871454 (a SNP in 100% LD with VKORC1) was significant
after correcting for multiple hypothesis testing.
Table 2 Univariate gene linear regression
Gene Name P-Value
VKORC1 Vitamin K1 2,3-epoxide reductase subunit 1 9.08E-07
CYP2C9 cytochrome P450, family 2, subfamily C 9.63E-05
NSUN6 NOL1/NOP2/Sun domain family 6 1.07E-02
UBE3A E6AP ubiquitin-protein ligase 1.35E-02
BRF1 B - related factor 1 1.39E-02
QTRTD1 queuine tRNA-ribosyltransferase domain
containing 1
1.54E-02
F8 Procoagulant component 2.40E-02
BAT5 HLA-B associated transcript 5 3.02E-02
COL1A2 Alpha-2 type I collagen 3.23E-02
RCN2 E6-binding protein 3.27E-02
Genes with candidate gene-scores that significantly predict dose in a
univariate linear regression model (p≤0.05). Genes in bold are significant after
correcting for multiple hypothesis testing.
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testing (Table 3).
A logistic regression classification model was trained
on VKORC1 and UBE3A gene-scores and evaluated
with 10-fold cross validation (Figure 1). The AUROC
was 0.721 (significance p-value < 0.01). A second logistic
regression classification model was trained on the 20
genes that had a p-value ≤ 0.05 (Figure 1). The AUROC
of this classifier was 0.886 (significance p-value < 0.01).
Analogously for the high-dose model, three genes
were found to have significant p-values after multiple
hypothesis testing, VKORC1, CYP2C9, and QTRTD1:
p-values of 4.4e-6, 2.3e-4, and 3.2e-4 respectively. 12
other genes had p-values ≤ 0.05 before multiple hypoth-
esis correction (Table 4).
A logistic regression classification model was trained
on VKORC1, CYP2C9, and QTRTD1 and evaluated
with 10-fold cross validation (Figure 2). The AUROC
was 0.693 (significance p-value < 0.01). A second logistic
regression classification model was trained on the 15
genes that had a p-value ≤0.05 (Figure 2). The AUROC
of this classifier was 0.764 (significance p-value < 0.01).
Discussion
In this study we present a novel method for integrating
pre-existing pharmacological knowledge and scoring
candidate genes from association studies. We have
demonstrated that this filtering and scoring method is
capable of identifying candidate genes explaining a large
proportion of warfarin dose response phenotypes.
Our pHap value is a simple measure of how “extreme”
an individual’s variants are in a particular gene: if all the
SNPs show minor alleles, then the individual has a very
high pHap value for that gene. If all the SNPs show
major alleles, then the individual has a low value for
that gene. We have shown that this aggregate measure
of genotype has the advantage of aggregating genetic
variation in order to reduce the number of hypotheses
tested. This measure cannot only increase the power to
identify candidate genes that explain dosage variation
but also can identify candidate genes for extreme
phenotypes.
We validate our methods on the warfarin GWAS
study by Cooper et al, which attempted to identify can-
didate genes by examining a SNPs ability to predict
dosage in a univariate linear regression model. The
power of the Cooper analysis, however, was limited by
the low number of patients in the cohort, a common
problem in drug GWAS [7]. When our methods were
applied to the same data set we were able to identify the
two best characterized genes responsible for variation in
warfarin dose response, VKORC1 and CYP2C9. It is
interesting to note that the knowledge filtration method
alone will not identify both of these two genes (Table
1). The pHap, which summarizes the aggregate contri-
bution of a set of SNPs, is also needed in order to iden-
tify CYP2C9 significantly (Table 2).
We also show that our method can significantly iden-
tify features for a machine learning classification algo-
rithm. We achieve high performance when classifying
between low/not low-dose patients and between high/
not-high dose patients (AUROCs of 0.886 and 0.764
respectively, Figures 1 and 2). Using an empirical boot-
strapping approach we demonstrated that the genes our
method identifies are significant. In both cases the
AUROC of the model was the highest observed, corre-
sponding to a p-value < 0.01.
We acknowledge that the described method is depen-
dant being able to identify potentially important phar-
macogenes. It is important to note that the algorithm
we employed to rank genes for their potential to be
pharmacogenomic does not require the drug to be pre-
viously known and will predict pharmacogenes for novel
chemical structures.
The results of this study offer support for the applic-
ability of allele-based pharmacogenetic models for the
prediction of drug response phenotype. In addition, it
opens up new avenues for candidate pharmacogene dis-
covery. In future work we plan to improve our method
through the investigation of more sophisticated
Table 3 Low/not low model
Gene Name P-Value
UBE3A E6AP ubiquitin-protein ligase 5.39E-05
VKORC1 Vitamin K1 2,3-epoxide reductase subunit 1 1.16E-04
SLA2 Src-like adapter protein 2 2.11E-03
DICER1 Dicer1, Dcr-1 homolog 3.76E-03
CYP2C9 cytochrome P450, family 2, subfamily C 5.49E-03
SLC22A1 solute carrier family 22 1.12E-02
BBC3 BCL2 binding component 3 1.49E-02
F8 Procoagulant component 1.74E-02
HMOX2 heme oxygenase (decycling) 2 1.79E-02
MUTED muted homolog 1.99E-02
VWF coagulation factor VIII VWF 2.40E-02
HSD3B7 3-beta-HSD VII 2.56E-02
SPIN1 spindlin 1 2.58E-02
SELPLG selectin P ligand 2.89E-02
FAM113B family with sequence similarity 113, member B 2.92E-02
F13B Fibrin-stabilizing factor B subunit 3.36E-02
MVP major vault protein 3.39E-02
UGT2B7 UDP glucuronosyltransferase 2B7 3.83E-02
AKR7A2 aflatoxin beta1 aldehyde reductase 4.17E-02
SERTAD1 CDK4-binding protein p34SEI 4.96E-02
Top 20 genes with candidate gene-scores that significantly distinguish
between low dose patients and non-low-dose patients (p≤0.05). P-Values are
result of t test between low-dose and non-low-dose distributions of gene-
scores. Genes in bold are significant after correcting for multiple hypothesis
testing.
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g e n e t i ca n dg e n o m i cf e a t u r e sp r e d i c t i v eo fd r u g
response. We will also seek to expand the application of
our method to additional drugs, with the overarching
aim of developing a method that is predictive and
robust across a broad range of drugs. We also plan to
investigate the warfarin-associated pharmacogenes iden-
tified by our approach and work to biologically validate
their putative role in warfarin response.
Conclusions
We have developed a novel approach that incorporates
pharmacogenomic knowledge integration and a gene
scoring system based on SNP aggregation to enhance
pharmacogene discovery from pharmacogenomics
GWAS. We applied this approach to a published warfarin
GWAS data set comprising 181 individuals and found
that our method can increase the power of the GWAS to
identify established warfarin pharmacogenes VKORC1
and CYP2C9, and implicate several novel warfarin phar-
macogenes. Additionally, we find that our method can be
Figure 1 Low Dose Classification ROC Curve. Receiver Operating Characteristic Curve for the low dose classification algorithms. Two classifiers
were trained, the first, dotted line, on all 20 genes for which the gene-scores significantly distinguish low-dose and non-low-dose patients
(AUROC=0.886, p≤0.05, Table 3), and the second, dashed line, on only those genes that were significant after multiple hypothesis testing
correction (AUROC=0.721, p≤0.001, Table 3). Both classifiers have empirical p-value significance of less than 0.01 when tested using
bootstrapping.
Table 4 High/not high model
Gene Name P-Value
VKORC1 Vitamin K1 2,3-epoxide reductase subunit 1 4.39E-06
CYP2C9 cytochrome P450, family 2, subfamily C 2.27E-04
QTRTD1 queuine tRNA-ribosyltransferase domain 3.21E-04
NAT13 N-acetyltransferase 13 5.25E-03
BAT5 HLA-B associated transcript 5 6.76E-03
CRP C-reactive protein, pentraxin-related 1.02E-02
COL1A2 Alpha-2 type I collagen 1.37E-02
GGCX Vitamin K gamma glutamyl carboxylase 1.44E-02
A2M C3 and PZP-like alpha-2-macroglobulin 2.06E-02
FBXO28 F-box protein 28 2.14E-02
HSD3B7 3-beta-HSD VII 2.54E-02
ITGA5 Fibronectin receptor subunit alpha 4.07E-02
ALS2 amyotrophic lateral sclerosis 2 4.13E-02
NSUN6 NOL1/NOP2/Sun domain family 6 4.21E-02
SORBS3 sorbin and SH3 domain containing 3 4.99E-02
Top 15 genes with candidate gene-scores that significantly distinguish
between high dose patients and non-high-dose patients (p≤0.05). P-Values are
result of t test between low-dose and non-low-dose distributions of gene-
scores. Genes in bold are significant after correcting for multiple hypothesis
testing.
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and high-dose (AUROC=0.764) responders, establishing
a basis of direct clinical utility for the approach. Based on
the performance observed with the warfarin GWAS, we
recommend future work to extend the approach and
apply it to additional pharmacogenomic GWAS as well
as GWAS characterising other traits of clinical interest.
Methods
Warfarin GWAS data
For validation, a dataset of 181 patient genotypes (175
Caucasian, 6 Hispanic) and stable warfarin dosages was
obtained from a warfarin GWAS study described by
Cooper et al. [15]. The list of SNPs measured by the
Cooper et al. study was filtered so that the set of SNPs
had a maximum pairwise r-squared linkage disequili-
brium score of 0.2. The resulting set was then queried
against the SCAN SNP and CNV Annotation Database
to determine whether the SNPs were either contained
within a given gene or within 5kbp upstream or down-
stream of that gene. One exception to the SCAN SNP
mapping was made so that rs10871454 mapped to
VKORC1. This SNP is in perfect linkage disequilibrium
with rs9923231, a VKORC1 SNP [15].
Using knowledge to limit the hypothesis testing space
GWAS studies are hindered by multiple hypothesis test-
ing corrections that significantly limit the power of ana-
lysis on smaller patient data sets. Pharmacogenomic
knowledge bases integrate large amounts of data from
the literature and biological experiments. Recently, an
algorithm, called the PGxPipeline, was published that
integrates pharmacogenomics and drug-binding data-
bases to rank genes for their likelihood to be pharmaco-
genomic for a given drug [17]. The PGxPipeline was
used to rank genes for their likelihood to be involved in
the pharmacokinetics or pharmacodynamics of warfarin
metabolism and action. This ranking of genes was then
repeated for each of 486 other drugs for which pharma-
cogenetic interactions are known. These other drug
gene rankings were then used to apply a significance
score to the warfarin gene rankings. Only the most sig-
nificant (p-value ≤ 0.05) warfarin genes were used the
following analysis. 786 such genes were identified to
have significant likelihood scores to be potential war-
farin pharmacogenes. Of those, 228 contained SNPs that
were measured by the Cooper GWAS study. We define
this genes set to be the Warfarin-Specific Pharmacogen-
ome (WSP). We limited our analysis to just those 3,856
Figure 2 High Dose Classification ROC Curve. Receiver Operating Characteristic Curve for the high dose classification algorithms. Two
classifiers were trained, the first, dotted line, on all 15 genes for which the gene-scores significantly distinguish high-dose and non-high-dose
patients (AUROC=0.764, p≤0.05, Table 3), and the second, dashed line, on only those genes that were significant after multiple hypothesis
testing correction (AUROC=0.693, p≤0.001, Table 3). Both classifiers have empirical p-value significance of less than 0.01 when tested using
bootstrapping.
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regression analysis used in the Cooper study was
repeated for these 3,856 SNPs (Table 1).
Derivation and evaluation of a candidate gene-score
based on allele frequencies
We aggregated he 3,856 SNPs by gene and a computed
the gene-score for each gene based on the SNP allele
frequencies. These features are based on the straightfor-
ward assumption that genes with a preponderance of
low-frequency alleles in individuals with extreme drug
response phenotypes are more likely to be modulating
that response [18]. Variants of pharmacogenes are
important in determining drug response. As a proxy to
the potential of variants in a pharmacogene to effect
drug response we define the pHap score. To calculate
the pHap score for a given patient and a given gene we
first compute the negative log of each genotype fre-
quency for each SNP in the given gene. We then take
the sum of these values and call this the pHap score.
The pHap score for patient, i, and gene, j, is defined as
pHap f ij ijk
k
N j
,, , () =∑log
where Nj is the number of SNPs in gene j and fi,j,k is
the frequency of the allele of patient i for SNP k of gene
j. Therefore, there is a pHap score for each gene in the
WSP for each patient. In total we generated 228 pHap
scores for each patient (for the 228 included genes). We
then fit each gene-score in a univariate linear regression
model to the dosage data and tested for the gene-score’s
ability to predict the dosage data (Table 2).
Redefinition to a classification problem
To test the method’s ability to identify genomic features
that are predictive of phenotypes the patients were divided
into classes based on their stable dose. The first two classes
consisted of patients who required a low stable dose of
warfarin (≤3mg/day) and the compliment set of patients.
The latter two classes consisted of patients who required a
high stable dose of warfarin (≥7mg/day) and the compli-
ment set of patients. Dividing the patients into these two
sets of classes (low/not low and high/not high) redefines
the task as a classification problem. This allows us to train
machine-learning algorithms on the features identified by
our method and, if the features are discriminatory, predict
the drug response classification of the patient.
Identification of features to distinguish extreme dose
patients
Patients were divided into two classes, those that
required a low stable dose of warfarin and those who
did not. For each patient we calculated the gene-score
of each gene and tested for the two classes of scores for
the null hypothesis using a Students t test. Since 228
null hypotheses were being tested the p-values were cor-
rected using the conservative Bonferroni multiple
hypothesis correction method. The new threshold for
significance was set at 0.001 (Table 3).
We trained two logistic regression classifiers. The first
classifier we trained was on only the genes that were
significant after correcting for multiple hypothesis test-
ing and the second was trained on all genes that had a
p-value ≤ 0.05. The classifiers were evaluated using 10-
fold cross validation. In 10-fold cross validation the clas-
sifier is trained on 9/10th of the data and the remaining
1/10th of the data is reserved to evaluate the perfor-
mance of the classifier. This process is repeated 10
times and the average performance is plotted in a recei-
ver operating characteristic (ROC) curve. The area
under the ROC curve (AUROC) is a summary statistic
for overall the performance of the classifier (Figure 1).
In order to evaluate the significance of the classifica-
tion models an empirical p-value was derived. To derive
an empirical p-value, we trained the classifiers on ran-
domly chosen genes from the set of 228 in the WSP.
The number of genes chosen at random corresponded
to the number of genes used in the two classifiers. We
repeated this process 100 times for each classifier.
The analogous analysis was repeated for the high-
dose/not-high-dose patient classifications (Table 4, Fig-
ure 2).
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